Chemotherapy-mediated lncRNA-induced immune cell plasticity in cancer immunopathogenesis DOI

Jingyuan Lu,

Haowei Ma, Qian Wang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 141, P. 112967 - 112967

Published: Aug. 24, 2024

Language: Английский

Recent progress and the emerging role of lncRNAs in cancer drug resistance; focusing on signaling pathways DOI
Mohamed J. Saadh,

Irodakhon Rasulova,

Mohammad Ali Abdullah Almoyad

et al.

Pathology - Research and Practice, Journal Year: 2023, Volume and Issue: 253, P. 154999 - 154999

Published: Nov. 29, 2023

Language: Английский

Citations

5

PD-1/PD-L1 Inhibitors Response in Triple-Negative Breast Cancer: Can Long Noncoding RNAs Be Associated? DOI Open Access
Carolina Mathias, Vanessa Nascimento Kozak, Jessica Maria Magno

et al.

Cancers, Journal Year: 2023, Volume and Issue: 15(19), P. 4682 - 4682

Published: Sept. 22, 2023

As immune checkpoint inhibitors (ICI) emerge as a paradigm-shifting treatment option for patients with advanced or metastatic cancer, there is growing demand biomarkers that can distinguish which are likely to benefit. In the case of triple-negative breast cancer (TNBC), characterized by lack therapeutic targets, pembrolizumab approval high-risk early-stage disease occurred regardless PD-L1 status, keeps condition in biomarker limbus. this review, we highlight participation long non-coding RNAs (lncRNAs) regulation PD-1/PD-L1 pathway, well definition prognostic immune-related signatures many types tumors, aiming shed light on molecules deserve further investigation potential role biomarkers. We also conducted bioinformatic analysis investigate lncRNAs already investigated PD-1/PDL-1 pathways other types, considering TNBC molecular context. sense, from generated data, evidence here two lncRNAs, UCA1 and HCP5, have not yet been identified context tumoral response cancer. These candidates be explored verify their use ICI response. article, present an updated review regarding lncRNA ICI, highlighting versatility using these molecules.

Language: Английский

Citations

4

Targeting CERS6-AS1/FGFR1 axis as synthetic vulnerability to constrain stromal cells supported proliferation in Mantle cell lymphoma DOI

Udita Jindal,

Mukesh Mamgain,

Uttam Kumar Nath

et al.

Leukemia, Journal Year: 2024, Volume and Issue: 38(10), P. 2196 - 2209

Published: July 13, 2024

Language: Английский

Citations

1

Unveiling the nexus: Long non-coding RNAs and the PI3K/Akt pathway in oral squamous cell carcinoma DOI
Naji Naseef Pathoor,

Pitchaipillai Sankar Ganesh

Pathology - Research and Practice, Journal Year: 2024, Volume and Issue: 262, P. 155540 - 155540

Published: Aug. 12, 2024

Language: Английский

Citations

1

Chemotherapy-mediated lncRNA-induced immune cell plasticity in cancer immunopathogenesis DOI

Jingyuan Lu,

Haowei Ma, Qian Wang

et al.

International Immunopharmacology, Journal Year: 2024, Volume and Issue: 141, P. 112967 - 112967

Published: Aug. 24, 2024

Language: Английский

Citations

1